Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer

International Journal of Nanomedicine

Volumn 12, Issue , 2017, Pages 1699-1715

  Liang, Yan ^a   Tian, Baocheng ^a   Zhang, Jing ^a   Li, Keke ^a   Wang, Lele ^a   Han, Jingtian ^a   Wu, Zimei ^b  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b YANTAI UNIVERSITY   (China)

Author keywords

Cancer targeting; Combination treatment; Nanostructured lipid carriers; Polymer drug conjugate; Ratiometric drug loading

Indexed keywords

DRUG CARRIER; GEMCITABINE; LIPID; N ACETYLGLUCOSAMINE; NANOMATERIAL; PACLITAXEL; POLY(6 O METHACRYLOYL D GALACTOPYRANOSE); POLYSACCHARIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOMATERIAL; DEOXYCYTIDINE; GALACTOSE; POLYMER;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMICAL PHENOMENA; CONFOCAL LASER SCANNING MICROSCOPY; CONJUGATE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY ASSAY; DISPERSITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; EMULSION; ENDOCYTOSIS; EVAPORATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; IC50; LUNG NEOPLASMS; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOCOMPATIBLE MATERIALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ENDOCYTOSIS; GALACTOSE; HUMANS; INHIBITORY CONCENTRATION 50; LIPIDS; LUNG NEOPLASMS; MICE; NANOSTRUCTURES; PACLITAXEL; POLYMERS;

EID: 85014563338     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S121262     Document Type: Article

References (45)

1. Ding Y, Qiao Y, Wang M, et al. Enhanced neuroprotection of acetyl-11-keto-β-boswellic acid (AKBA)-loaded O-carboxymethyl chitosan nanoparticles through antioxidant and anti-inflammatory pathways. Mol Neurobiol. 2016;53(6):3842-3853.
2. Hashem FM, Al-Sawahli MM, Nasr M, Ahmed OA. Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems: enhancement of oral bioavailability. Drug Des Devel Ther. 2015;9:3141-3152.
3. Mancarella S, Greco V, Baldassarre F, Vergara D, Maffia M, Leporatti S. Polymer-coated magnetic nanoparticles for curcumin delivery to cancer cells. Macromol Biosci. 2015;15(10):1365-1374.
4. Shi F, Zhao Y, Firempong CK, Xu X. Preparation, characterization and pharmacokinetic studies of linalool-loaded nanostructured lipid carriers. Pharm Biol. 2016;54(10):2320-2328.
5. Zhou J, Zhou D. Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers. Drug Des Devel Ther. 2015;9:5269-5275.
6. Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv. 2016;23(8):2720-2725.
7. Song A, Su Z, Li S, Han F. Nanostructured lipid carriers-based flurbiprofen gel after topical administration: acute skin irritation, pharmacodynamics, and percutaneous absorption mechanism. Drug Dev Ind Pharm. 2015;41(9):1488-1492.
8. Zhang C, Peng F, Liu W, et al. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int J Nanomedicine. 2014;9:1049-1063.
9. Han F, Yin R, Che X, et al. Nanostructured lipid carriers (NLC) based topical gel of flurbiprofen: design, characterization and in vivo evaluation. Int J Pharm. 2012;439(1):349-357.
10. Song J, Fan X, Shen Q. Daidzein-loaded nanostructured lipid carriers-PLGA nanofibers for transdermal delivery. Int J Pharm. 2016;501(1): 245-252.
11. Liu X, Wang Z, Feng R, Hu Y, Huang G. A novel approach for systematic delivery of a hydrophobic anti-leukemia agent tamibarotene mediated by nanostructured lipid carrier. J Biomed Nanotechnol. 2013; 9(9):1586-1593.
12. Ranpise NS, Korabu SS, Ghodake VN. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces. 2014;116:81-87.
13. Gu X, Zhang W, Liu J, et al. Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells. AAPS PharmSciTech. 2011;12(4):1200-1208.
14. Baykara M, Coskun U, Berk V, et al. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer. Asian Pac J Cancer Prev. 2012;13(10):5119-5124.
15. Kroep JR, Smit EF, Giaccone G, et al. Pharmacology of the paclitaxelcisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2006;58(4):509-516.
16. Shord SS, Faucette SR, Gillenwater HH, et al. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003;51(4):328-336.
17. Fogli S, Danesi R, De Braud F, et al. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol. 2001; 12(11):1553-1559.
18. Miao L, Guo S, Zhang J, Kim WY, Huang L. Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv Funct Mater. 2014;24(42):6601-6611.
19. Kroep JR, Giaccone G, Tolis C, et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer. 2000; 83(8):1069-1076.
20. Tardi PG, Dos Santos N, Harasym TO, et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther. 2009;8(8):2266-2275.
21. Duan X, Xiao J, Yin Q, et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano. 2013;7(7):5858-5869.
22. Ding Y, Han J, Tian B, et al. Hepatoma-targeting and pH-sensitive nanocarriers based on a novel D-galactopyranose copolymer for efficient drug delivery. Int J Pharm. 2014;477(1):187-196.
23. Pawar S, Vavia P. Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin. J Drug Target. 2016; 24(1):68-79.
24. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005; 202(3):654-662.
25. Pawar SK, Vavi P. Efficacy interactions of PEG-DOX-N-acetyl glucosamine prodrug conjugate for anticancer therapy. Eur J Pharm Biopharm. 2015;97(Pt B):454-463.
26. Pawar SK, Badhwar AJ, Kharas F, Khandare JJ, Vavia PR. Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery. Int J Pharm. 2012;436(1):183-193.
27. Gu X, Zhang W, Liu J, et al. Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells. AAPS PharmSciTech. 2011;12(4):1200-1208.
28. Cavallaro G, Licciardi M, Caliceti P, Salmaso S, Giammona G. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. Eur J Pharm Biopharm. 2004;58(1): 151-159.
29. Cavallaro G, Licciardi M, Salmaso S, Caliceti P, Gaetano G. Folate-mediated targeting of polymeric conjugates of gemcitabine. Int J Pharm. 2006;307(2):258-269.
30. Wang Y, Hong CY, Pan CY. Galactose-based amphiphilic block copolymers: synthesis, micellization, and bioapplication. Biomacromolecules. 2013;14(5):1444-1451.
31. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681.
32. Deutsch HM, Glinski JA, Hernandez M, et al. Synthesis of congeners and prodrugs - 3: water-soluble prodrugs of taxol with potent antitumor activity. J Med Chem. 1989;32(4):788-792.
33. Guo ZW, Gallo JM. Selective protection of 2′,2′-difluorodeoxycytidine (gemcitabine). J Org Chem. 1999;64(22):8319-8322.
34. Lv S, Tang Z, Li M, et al. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials. 2014;35(23):6118-6129.
35. Lv S, Tang Z, Zhang D, et al. Well-defined polymer-drug conjugate engineered with redox and pH-sensitive release mechanism for efficient delivery of paclitaxel. J Control Release. 2014;194:220-227.
36. Yang Q, Yang Y, Li L, et al. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer. ACS Appl Mater Interfaces. 2015;7(12):6661-6673.
37. Lee SM, O’Halloran TV, Nguyen ST. Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J Am Chem Soc. 2010;132(48):17130-17138.
38. Luo S, Gu Y, Zhang Y, et al. Precise ratiometric control of dual drugs through a single macromolecule for combination therapy. Mol Pharm. 2015;12(7):2318-2327.
39. Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854-1863.
40. Krishnamurthy S, Ng VW, Gao S, Tan MH, Yang YY. Phenformin-loaded polymeric micelles for targeting both cancer cells and cancer stem cells in vitro and in vivo. Biomaterials. 2014;35(33):9177-9186.
41. Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release. 2001;70(1):63-70.
42. Xu XY, Lu L, Zhou JP, et al. Preparation and characterization of N-succinyl-N′-octyl chitosan micelles as doxorubicin carriers for effective anti-tumor activity. Colloids Surf B Biointerfaces. 2007; 55(2):222-228.
43. Liu Y, Fang J, Kim YJ, Wong MK, Wang P. Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm. 2014;11(5):1651-1661.
44. Jia J, Zhu F, Ma X, et al. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8(2):111-128.
45. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49(16):4373-4384.